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AbstrAct
To understand how mitochondria are involved in malignant transformation 
we have generated a collection of transmitochondrial cybrid cell lines on the same 
nuclear background (143B) but with mutant mitochondrial DNA (mtDNA) variants 
with different degrees of pathogenicity. These include the severe mutation in the 
tRNALys gene, m.8363G>A, and the three milder yet prevalent Leber’s hereditary optic 
neuropathy (LHON) mutations in the MT-ND1 (m.3460G>A), MT-ND4 (m.11778G>A) 
and MT-ND6 (m.14484T>C) mitochondrial genes. We found that 143B ρ0 cells devoid 
of mtDNA and cybrids harboring wild type mtDNA or that causing severe mitochondrial 
dysfunction do not produce tumors when injected in nude mice. By contrast cybrids 
containing mild mutant mtDNAs exhibit different tumorigenic capacities, depending 
on OXPHOS dysfunction.
The differences in tumorigenicity correlate with an enhanced resistance to 
apoptosis and high levels of NOX expression. However, the final capacity of the 
different cybrid cell lines to generate tumors is most likely a consequence of a complex 
array of pro-oncogenic and anti-oncogenic factors associated with mitochondrial 
dysfunction. 
Our results demonstrate the essential role of mtDNA in tumorigenesis and explain 
the numerous and varied mtDNA mutations found in human tumors, most of which 
give rise to mild mitochondrial dysfunction.
INtrODUctION
Cancer is a complex disease triggered by a variety 
of factors, including mutations in proto-oncogenes and 
tumor suppressor genes. As a consequence, cancer cells 
deregulate their cell cycle and impair apoptosis, promoting 
a higher proliferation rate that leads to the accumulation of 
a cell mass [1]. A key feature of cancer cells is their ability 
to reprogramme metabolism in order to adapt it to rapid 
proliferation and exponential growth. This is achieved by 
increasing aerobic glycolysis, the well-known Warburg 
effect, which supplies the metabolic intermediates 
used in anabolic processes [2, 3]. In addition, oxidative 
phosphorylation (OXPHOS) is downregulated in most 
cancer cells, the combination of high glycolysis and low 
OXPHOS (the bioenergetic signature) becoming a feature 
used to diagnose early stages of cancer and as a marker of 
tumor progression [4]. 
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The discovery of altered mitochondria in tumor 
tissues has stimulated studies on the relationship between 
mitochondria and cancer [5-7]. Accordingly, mutations 
in nuclear genes encoding enzymes of the Krebs 
cycle have been found in hereditary paragangliomas, 
pheochromocytomas and among other human tumors [8-
10]. In addition, the recent massive sequencing of tumor 
and non-tumor tissues pairs performed by The Cancer 
Genome Atlas (TCGA) consortium identified numerous 
mutations in the mtDNA of cancer cells, although vast 
majority seems to provoke non severe dysfunctions. 
This suggests that mtDNA variants could drive 
metabolic alterations that are important in the malignant 
transformation, although the full pathological significance 
of these observations remains unclear [11-13]. 
In normal cells, most cellular ATP is produced in 
the mitochondria by the OXPHOS system, which is 
comprised of the electron transport chain complexes (plus 
two electron carriers: coenzyme Q and cytochrome c) and 
the multimeric ATP-synthase (complex V). OXPHOS 
biogenesis requires the coordinated expression of two 
genomes, the nuclear and mitochondrial. Mitochondrial 
DNA (mtDNA) encodes a limited but essential number 
of genes for OXPHOS biogenesis, including the RNA 
components of the translational apparatus, two rRNAs 
(12S and 16S) and twenty two tRNAs, along with thirteen 
proteins, all of which are subunits of the I, III, IV and 
V complexes of the OXPHOS system. Due to their dual 
genetic control, OXPHOS alterations (which provoke the 
so-called OXPHOS diseases or mitochondrial diseases) 
can be caused by mutations in mitochondrial and/or 
nuclear DNA. The mtDNA accumulates mutations, many 
of them cause moderate or no phenotypic effects, while 
others cause severe diseases [14].
Human mitochondrial diseases are characterized 
by a wide variety of symptoms and they affect different 
organs. To date, over 250 pathogenic mutations have 
been identified within the human mitochondrial genome 
affecting genes encoding rRNAs, tRNAs and proteins. 
mtDNA mutations may cause multisystemic syndromes, 
such as in most tRNA mutations, or they may affect 
specific organs [14]. A paradigmatic tissue-specific 
mitochondrial disease is Leber´s hereditary optic 
neuropathy (LHON), caused by non-severe mutations in 
genes encoding complex I subunits that provoke severe 
visual impairment due to retinal ganglion cell death. 
Mutations in three polypeptides are responsible for 90-
95% of all cases of LHON: MT-ND1 (m.3460G>A), MT-
ND4 (m.11778G>A) and MT-ND6 (m.14484T>C) [15, 
16]. 
In addition to their role in cellular energy 
production, mitochondria are metabolic signaling centers 
that fulfil a variety of essential functions including 
apoptosis, ROS production and calcium homeostasis in 
different cells and tissues [17]. However, the fundamental 
molecular mechanisms underlying these processes, which 
are critical to understand the role of mitochondria in health 
and disease, are mostly unknown. Cytoplasmic hybrids, 
also known as transmitochondrial cybrids or cybrids, 
represent models that are being used widely to study the 
effects of mtDNA variants on cell physiology and human 
pathology [18, 19]. These cells are generated by fusing 
mtDNA depleted cells (ρ0 cells) with cytoplasts, typically 
platelets or enucleated fibroblasts [20]. 
The first studies into cancer involving mtDNA 
variants were done before the development of ρ0 cells and 
therefore, they were prior to the currently available cybrid 
technology. In those studies, the tumorigenic properties 
of a cell line were modified by altering its cytoplasmic 
content [21, 22]. Subsequently, cybrid technology has 
been used to examine the relationship between mtDNA 
and tumorigenicity in different cell lines and for a variety 
of mtDNA mutations. These studies suggested different 
mechanisms are at play in tumor development, involving 
changes in ROS levels, Hif-1α stabilization, sensitivity to 
apoptosis, etc., but not in a conclusive manner [23-29]. In 
addition, the literature is not always coherent regarding 
such correlations, in most cases because these analyses 
studied the effect of a unique mutation in reference to a 
unique control and in only one cybrid clone. 
To clarify this controversy, in this work we have 
analyzed a group of parameters in at least two clones of 
every cell line of a wide panel of 143B osteosarcoma-
derived cybrids harboring several mtDNA mutations and 
their corresponding controls . 
Our results clearly demonstrate that mtDNA 
genetic variants modulate the tumorigenicity of K-RAS 
transformed 143B osteosarcoma cells. The mtDNAs that 
render a functional OXPHOS and mutant mtDNAs that 
severely disrupt OXPHOS all suppress tumorigenicity, 
as does the depletion of mitochondria in 143B ρ0 cells. 
However, mtDNA mutations that impair OXPHOS but do 
not produce a loss-of-function all support tumorigenesis. 
Furthermore, in the homogeneous system of cybrid cell 
lines, the tumorigenic potential is directly correlated 
with the degree of OXPHOS impairment. This would 
explain the high number and variety of mtDNA mutations 
accumulation found in human tumors. Differences in 
the tumorigenic potential of 143B cybrids are correlated 
with resistance to apoptosis and strong NOX expression, 
which is most likely modulated by a complex array of 
pro-oncogenic and anti-oncogenic factors derived from 
mitochondrial dysfunction. 
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rEsULts AND DIscUssION
the 143b cell line requires mtDNA to induce 
tumor formation
The 143B cell line, generated by transforming TE85 
human osteosarcoma cells with a K-ras oncogene, has 
been used in numerous studies as a cancer model given its 
ability to efficiently form tumors in nude mice, exhibiting 
considerable cell motility and invasive potential [30, 31]. 
More than twenty years ago a 143B TK- cell line was 
successfully used to generate a line devoid of mtDNA, the 
so called 143B ρ0 cell line, which was also functionally 
repopulated with mitochondria from donors [20]. The 
parental 143B cells contain a mtDNA molecule that 
belongs to haplogroup X and that harbors the homoplasmic 
m.6267G>A mutation in the cytochrome oxidase I (CO1) 
subunit, a mutation that impairs cytochrome c oxidase 
(COX) activity and respiration [32]. The m.6267G>A 
mutation has been associated with different types of 
cancer but it has yet to be associated with mitochondrial 
diseases. This is probably due to its weak impact on the 
OXPHOS function as revealed by its slightly decrease in 
MIMP (Mitochondrial Inner membrane Potential), ATP 
levels and oxygen consumption that do not affect their 
ability to grow in galactose (Figure 1). As expected, there 
was no mitochondrial activity in these 143B ρ0 cells.
The importance of mtDNA in the capacity of 143B 
cells to produce tumors was investigated by injecting 5 
x 106 143B or 143B ρ0 cells into nude mice. The 143B 
cells produced tumors at all injection sites within a 
relatively short period of 22 days (Figure 2), tumors that 
exhibited a high growth rate and that reached a size of 2 
cm2 in 42 days. By contrast, 143B ρ0 cells were unable to 
generate tumors, in accordance with the non-tumorigenic 
nature of other ρ0 cell lines [33] but in contrast to the 
proposed enhanced tumorigenicity of 143B ρ0 cells due 
to their anchorage independent growth [34]. These results 
demonstrate that the capacity of 143B cells to produce 
tumors is strictly dependent on the presence of mtDNA.
Figure 1: OXPHOs functional characterization of the different cell lines. (A) Growth curves in 0.9 g/L galactose showing 
severe OXPHOS dysfunction in the 143B ρ0 and m.8363G>A cell line. (b) Mitochondrial inner membrane polarization was evaluated 
as the ratio of Tetramethyl rhodamine ester (TMRE) to MitoTracker Green (MTG) assessed by flow cytometry. (c) Basal respiration. 
Oxygen Consumption was measured using the Oroboros oxygragh-2k. (D) Steady state mitochondrial ATP. Adenosine Triphosphate (ATP) 
was detected using the luminometric luciferin-luciferase method in cybrid samples incubated for 2h with 5mM 2-deoxy-D-glucose/1mM 
pyruvate. At least three independent experiments were measured for each parameter and the data represent the means and standard 
deviations. The haplogorup B of wild type is in parenthesis. The mean from two independent m.8363G>A clones is also shown. The data 
was analyzed using one way ANOVA and Tukey’s multiple comparison test, and a P-value <0.05 was considered significant: *=P ≤ 0.05, 
**=P ≤ 0.01, ***=P  ≤ 0.001.
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mtDNA rendering a functional or non-functional 
OXPHOs system do not support tumorigenicity 
To explore the possibility that mtDNA variants 
may modulate the tumorigenic properties of transformed 
cells, we investigated the tumorigenicity of cybrids 
harboring the well-known, severe mutation m.8363G>A. 
The m.8363G>A mutation in the mitochondrial tRNALys 
gene severely impairs the synthesis of mitochondrial 
proteins, yielding a non-functional respiratory chain [18]. 
Like 143B ρ0 cells, cybrids repopulated with mtDNA 
harboring the m.8363G>A mutation do not respire or 
produce mitochondrial ATP, and they therefore die in 
galactose medium (Figure 1). However, these cells are 
not tumorigenic (Figure 2), indicating that not only the 
absence of mtDNA but also a severe mtDNA mutation 
that fully impairs OXPHOS function acts as a tumor 
suppressor. Interestingly, control cybrids containing wild 
type mtDNA also showed weak tumorigenic behavior, 
inducing only small tumors at less than 20% of the 
injection sites, with slow growth rates and long latencies 
(above 63 days, Figure 2). These results suggest that the 
specific mtDNA in 143B cells is essential to define their 
tumorigenicity. Thus, mtDNAs that render either fully 
functional or non-functional OXPHOS systems do not 
support tumorigenicity, in contrast to the m.6267G>A 
mutation that only mildly impairs OXPHOS function.
Figure 2: the 143b osteosarcoma cell line exerts its tumorigenic potential through the mild mutation m.6267G>A. 
(A) Tumor growth induced by injection of 5x106 cells at each site, expressed as the mean for all the tumors generated by each genotype ± 
standard deviation. (b) Summary of the different clones and experiments carried out. The table records the number of tumors developed 
larger than 0.25 cm2 at the end of the experiment relative to the total number of injection sites. The latency period was defined as the 
time needed for the tumors to reach a size of 0.75 cm2. (c) Representative images of mice injected with the different cell lines. Note the 
difference in tumor growth in animals injected with 143B cells. The days after the injection are shown in parentheses.
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mtDNA harboring mild mutations supports 
tumorigenicity in function of the degree of 
OXPHOs impairment
To investigate the relationship between mild mtDNA 
mutations and tumorigenicity, we generated cybrids 
harboring the prevalent LHON mutations and their 
respective control cell lines. Studies into the pathological 
consequences of LHON mutations show that the same 
homoplasmic mutation may affect some individuals (even 
leading to blindness) while not affecting others at all 
[16]. Therefore, prevalent LHON mutations are excellent 
examples of mild mtDNA alterations that affect OXPHOS 
but that do not necessarily give rise to significant 
phenotypic manifestations, such as the m.6267G>A. 
Thus, we repopulated 143B ρ0 cells with mtDNA 
harboring the well characterized mutations m.3460G>A 
(MT-ND1), m.11778G>A (MT-ND4) and m.14484T>C 
(MT-ND6), which belong to V, HV* and Uk1 haplogroups, 
respectively as well as wild type mtDNAs for each of 
those haplogroups. Since the biochemical parameters and 
in vitro growth of cells harboring the different wild type 
versions of mtDNA (V, H and Uk1) were comparable, they 
were grouped in a single category (Figure 3). Compared 
to the wild type cells, cybrids harboring mtDNAs carrying 
LHON mutations showed reduced MIMP, basal respiration 
and mitochondrial ATP, as well as impaired growth in 
galactose. Thus, the functional impact of the three LHON 
mutations on the OXPHOS system was moderate, as 
reported previously [16].
Injection of nude mice with the cybrid lines 
demonstrated that the different mtDNA genetic variants 
confer variable tumorigenicity to the 143B nuclear 
background (Figure 4). All LHON cybrids were 
tumorigenic, although to a different extent. Cybrids 
containing the m.14484T>C mutation rapidly produced 
tumors at 95% of injection sites within 28 days, a behavior 
similar to that of the parental 143B cells (Figure 2). The 
tumorigenic potential of m.11778G>A cybrids was more 
Figure 3: Functional characterization of the different LHON cybrid cell lines and their controls. (A) Growth curves in 0.9 
g/L galactose (b) Mitochondrial inner membrane polarization was evaluated as the Tetramethyl rhodamine ester (TMRE) to MitoTracker 
Green (MTG) ratio, assessed by flow cytometry. (c) Basal respiration. Oxygen Consumption was measured using the Oroboros oxygragh-
2k. (D) Steady state Mitochondrial ATP in cybrid cells. ATP was detected using the luminometric luciferin-luciferase method in cybrid 
samples incubated for 2h with 5mM 2-deoxy-D-glucose/1mM pyruvate. The data for cybrids harboring mtDNA mutations are the mean of 
two clones and the three cybrid clones harboring wild type molecules were grouped. Each clone was measured in at least three independent 
experiments for each parameter and the mtDNA haplogroups are showed in parentheses. The data are the means ± standard deviation, and 
they were analyzed using one way ANOVA and Tukey’s multiple comparison test, with a P-value <0.05 considered to be significant: *=P 
≤ 0.05, **=P ≤ 0.01, ***=P ≤ 0.001.
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moderate, inducing tumors at 67% of injection sites after 
about 47 days, although once formed these tumors grew 
very fast. Finally, there was a high incidence of tumors in 
cybrids harboring the m.3460G>A mutation (86% of sites) 
but with a long latency of 65 days and a slow growth rate. 
In contrast to these mutants, wild type V, H, Uk1 cybrids 
were weakly tumorigenic inducing small tumors at less 
than 40% of injection sites with a very slow growth rate 
and a latency above 70 days, consistent with the behavior 
of cybrids containing wild type mtDNA of the haplogroup 
B (Figure 2). 
Remarkably, the tumorigenic behavior of LHON 
cybrids was correlated with the degree of OXPHOS 
dysfunction exhibited by the cell lines. Thus, the 
m.3460G>A mutation was associated with the lowest 
tumorigenicity and OXPHOS traits more similar to those 
of the wild types, whereas the mutation m.14484T>C 
had the strongest tumorigenic properties and the weakest 
mitochondrial function. The m.11778G>A mutation 
displayed an intermediate behavior in terms of both 
tumorigenicity and OXPHOS function (Figures 3 and 4). 
These results confirm that mtDNA mutations that provoke 
less severe mitochondrial dysfunction are associated with 
stronger tumorigenicity and they suggest a correlation 
within a range of OXPHOS impairment. However, 
normal mtDNA that allows correct OXPHOS function 
and mutated mtDNA that provokes severe OXPHOS 
dysfunction both abolish tumorigenicity, acting as tumor 
suppressors. 
Mitochondrial mediated tumorigenicity acts 
through multiples pathways
Although it is accepted that cancer is a multifactorial 
genetic disease, many studies have focused on the 
relationship between mitochondria and cancer in cultured 
tumor cells, pointing to a single parameter as that 
Figure 4: Mild mtDNA mutations are required for tumorigenicity. (A) Tumor growth induced upon injection of 5x106 cells at 
each site, expressed as the mean for all the tumors generated of each genotype ± standard deviation. (b) Summary table with the different 
clones and experiments carried out. The table records the number of tumors developed (larger than 0.25 cm2) relative to the total number of 
injection sites at the end of the experiment. The latency period was defined as the time needed for tumors to reach a size of 0.75 cm2. (c) 
Representative images of mice injected with the different cell lines, with the days after the injection indicated in parentheses.
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mainly responsible for tumor formation, development 
and spreading. Thus, to gain a more complete vision of 
this process, we analyzed several pathways that may be 
involved in the differences observed in the tumorigenicity 
of our cell lines.
Figure 5: Mitochondrial mediated tumorigenicity acts through multiples pathways. (A) Western Blots probed for AKT, 
phospho-AKT, ERK and phospho-ERK 1/2. (b) Lactate levels measured in the media after 48h in culture. (C) Mitochondrial superoxide 
and cytoplasmic ROS levels measured by flow cytometry with the fluorescent probes mitoSOXTM and H2DCFDA respectively. In B and 
(c), wild type clones for the V, H and Uk1 haplogroups were grouped. For the mutants, the bars indicate the mean of two different clones. 
Measurements for each clone were performed in duplicate in three independent experiments and the error bars represent the standard 
deviations. The data were analyzed using one way ANOVA and Tukey’s multiple comparison test, and a P-value <0.05 was considered 
significant: *=P≤0.05, **=P≤0.01, ***=P ≤0.001. (D) Western Blot of HIF1α with α-tubulin used as a loading control. (E) Western Blot of 
NOX1 and phospho-Histone H2A.X with α-tubulin was used as a loading control.
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143b cybrids do not exhibit changes in ras signaling 
activity
Oncogenic Ras activates multiple signaling 
pathways that affect a wide variety of cellular processes 
that drive tumorigenesis, stimulating proliferation, 
suppressing apoptosis, and promoting migration and 
invasiveness, [35]. Since Ras signaling is constitutively 
activated in the parental 143B cells due to the expression 
of a K-ras oncogene, we investigated whether mtDNA 
alterations in our cybrid cell lines affected this pathway. 
Thus, we analyzed the levels of the phosphorylated 
extracellular signal regulated kinase (p-ERK1/2) and 
phosphorylated AKT (p-AKT), both of which are 
effectors of the two main pathways activated by Ras: 
the mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K) signaling pathways, 
respectively. No changes in the expression of p-ERK1/2 
and p-AKT were found in the different cybrids with 
respect to parental 143B cells (Figure 5A), indicating that 
mtDNA alterations do not modify Ras signaling activity 
in 143B cells. Since there is no a correlation between the 
activation of Ras-dependent MAPK or PI3K signaling and 
the tumorigenicity of the cybrid cell lines, the suppression 
of tumorigenicity in 143B ρ0, m.8363G>A, WT (B, V, H, 
Uk1) cybrids (Figures 2 and 4) is either independent of 
Ras, or it occurs downstream of p-AKT and p-ERK1/2 
effectors. These results are consistent with the evidence 
suggesting that activated MAPK signaling in human 
cancers and mouse models is not always associated with 
tumorigenesis [36].
the glycolytic shift correlates with tumorigenicity 
within a range of OXPHOs function
Increased lactate production is thought to favor 
tumorigenesis since it is used as a carbon source by 
neighboring tumor cells, and it induces metabolic 
reprogramming and angiogenesis. On the other hand, 
environmental acidosis facilitates invasion by degradation 
of the extracellular matrix. Indeed, the levels of lactate 
produced by tumors are correlated with increased 
metastasis, tumor relapse and poor clinical outcome 
[37]. Lactate production is higher in our cybrid cell 
lines harboring mild mtDNA mutations than in the 
corresponding controls, which may participate in their 
increased tumorigenic properties (Figure 5B). However, 
while not tumorigenic, the 143B ρ0 and the cell lines 
containing the severe m.8363G>A mutation produced 
more lactate, suggesting that additional dominant 
elements are present in these cases. It is possible that 
increased glycolytic flux promoted by mtDNA mutations 
may have a significant impact in reprogramming cancer 
cells. Indeed, the hypothesis that proto-oncogenes and 
tumor suppressors genes arose in evolution as metabolic 
regulators reinforce this idea [3].
tumorigenicity induced by mild mtDNA mutations 
is associated with an increase in mitochondrial and 
cytoplasmic rOs
There are many cellular sources of reactive oxygen 
species (ROS) within a cell, they can be generated as 
an OXPHOS byproduct in the mitochondria as well as 
in the cytoplasm by other metabolic processes or by the 
NADPH oxidases in response to specific signals. The role 
of ROS in tumorigenesis is far from fully understood. It 
is accepted that tumor formation strongly depends on the 
amount of ROS [42], affecting (and in turn affected by) 
different pathways, such as those associated with NOX1 
[43], ERK [44], NF-kB [45], AKT [46, 47], HIF1α [38] 
and SRC [48].
To evaluate the possible correlation between the 
level of ROS and the tumorigenic capacity of the cybrids 
we quantified the levels of mitochondrial superoxide anion 
(O2
- ) with MitoSOXTM and the levels of cytoplasmic ROS 
with H2DCFDA.
The m.8363G>A tRNALys gene mutation induces 
high levels of O2
- compared with 143B ρ0 cells (Figure 5C), 
even though they share similar mitochondrial bioenergetic 
function (Figure 1). m.8363G>A cybrids barely synthesize 
10-15% of mtDNA encoded proteins [18], probably 
enough to yield ROS generating subcomplexes. On the 
other hand, 143B ρ0 cells, which only synthesize nuclear 
encoded proteins yielding complex II and a partial 
complex V (only lacking the two small subunits ATP6-8), 
are incapable of generating ROS producing subcomplexes. 
143B cells containing m.6267G>A generate similar O2
- 
levels as cybrids harboring LHON mutations and more 
O2
- than control cybrids [15], yet surprisingly equivalent 
to the O2
- levels yielded by the specific control WT(B) 
cybrids (Figure 5C).
Cytoplasmic ROS, showed a similar behavior to 
mitochondrial superoxide levels. Cells harboring mild 
or severe mtDNA mutations showed an increase in 
H2DCFDA signal compared with controls and 143B ρ
0 
cells (Figure 5C).
In this cellular system, ROS levels are directly 
correlated with tumorigenicity unless mitochondrial 
function is severely diminished, such as when the 
m.8363G>A mutation is present, which is associated 
with high ROS production but not tumorigenicity. Thus, 
while the m.14484T>C cybrid is the strongest ROS 
producer and exhibited the strongest tumorigenicity, the 
less tumorigenic m.1178G>A and m.3460G>A cybrids 
produced less ROS (Figure 5C). 
HIF1α destabilization does not hamper tumorigenicity
Two hallmarks of malignant transformation are a 
high proliferation rate and increased resistance to hypoxic 
conditions [2]. Highly proliferative cancer cells in solid 
tumors usually outgrow their vascular network, limiting 
oxygen diffusion within the tumor and subjecting it to 
hypoxic stress. Hypoxia inducible factors (HIFs) promote 
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the metabolic switch towards aerobic glycolysis, neo-
vascularization, tumor progression and cell invasion. 
Thus, HIF1α expression and the downstream activation of 
a hypoxic stress response are common to many cancers, 
although surprisingly, HIF1α expression is correlated 
with lower cancer stage or decreased patient mortality 
in certain cancers [38]. Thus, the relevance of HIF1α in 
tumorigenesis remains controversial, with evidence that 
HIF1α does not markedly affect tumorigenesis [39] or that 
it may fulfil a central role in this process [25]. Studies with 
143B cybrids showed that severe affects on mitochondrial 
function decrease the stability of HIF1α, which impairs 
the development of the malignant phenotype [23-25]. This 
is based on the regulation of HIF1α levels by the activity 
of prolyl-hydroxylases (PHDs), which are in their turn 
regulated by the accumulation of TCA cycle intermediates 
(reflected in the α-ketoglutarate/succinate ratio) [8]. 
Our tumorigenic cybrid cell lines harboring LHON 
mutations exhibited lower levels of HIF1α protein than 
their non-tumorigenic controls (Figure 5D). This may be 
due to the impaired OXPHOS function being sufficient to 
promote α-ketoglutarate accumulation and PHD activation. 
Therefore, in this cell system the levels of HIF1α may 
contribute to tumorigenicity but not as a driving force. As 
a matter of fact, HIF1α protein levels were also reduced 
in non-tumorigenic 143B ρ0 and m.8363G>A cybrid 
cell lines (Figure 5D). These results are to some extent 
surprising given that the activity of PHDs is inhibited by 
mitochondrial ROS [38] and therefore, mtDNA mutants 
that produce higher ROS levels should have more stable 
HIF1α, which is not the case. This would also indicate 
that OXPHOS is more important in regulating PHDs 
than ROS, as suggested when comparing 143B ρ0 with 
m.8363G>A, where the high ROS levels produced by the 
latter do not rescue the low levels of HIF1α.
Regarding the role of HIF1α in tumorigenesis, our 
results are consistent with reports that HIF1α knockdown 
does not affect or even increases the growth of different 
human carcinomas [39] (references therein). Indeed, 
HIF1α may even act as a tumor suppressor, since it 
antagonizes MYC function [40] and it also stabilize p53 
[41].
tumorigenicity is associated to NOX1 levels
A possible nexus between mitochondrial ROS 
and tumorigenicity is the induction of NAPDH-oxidase 
1 (NOX1) expression as a consequence of retrograde 
signaling [43]. Members of the NOX family generate 
superoxide that is rapidly converted into hydrogen 
peroxide, which in turn may regulate target molecules, 
acting as a second messenger [49]. Nox1 expression is 
strongly increased in breast, ovarian and colon tumors 
[43, 50]. Moreover, its overexpression in cultured cells has 
been implicated in the stimulation of proliferation [51] and 
angiogenesis [52], and in the inhibition of apoptosis [50]. 
The analysis of NOX1 expression (Figure 5E) revealed 
that NOX1 expression was diminished in control cybrid 
cell lines and 143B ρ0 cells with low ROS levels. On 
the other hand, LHON mutations that impair but do not 
abolish OXPHOS (increasing ROS levels) up-regulate 
NOX1 expression. Strikingly, NOX1 levels are reduced in 
cell lines with severely diminished mitochondrial function 
(due to the presence of the m.8363G>A point mutation). 
Thus, NOX1 levels are correlated with tumorigenicity. 
NOX1 expression is related to superoxide levels, 
except in m.8363G>A cybrids in which the decrease in 
NOX1 expression triggered by the m.8363G>A mutation is 
not compensated by an increase in ROS levels (Figure 5). 
Hence, NOX1 expression appears not only to be regulated 
by ROS [43]. Therefore, the lack of NOX1 in 143B ρ0 
cells may be caused by either decreased mitochondrial 
ROS levels or by a deficiency in mitochondrial function.
Furthermore, the correlation between cytoplasmic 
and mitochondrial ROS levels could be explained at least 
in part by the induction of NOX1 expression by the latter: 
the mitochondrial ROS levels increase NOX1 expression 
which raises cytoplasmic ROS, suggesting a signal 
transduction role for NOX1.
In our model, the correlation between NOX1 
and tumorigenicity may be related to its importance in 
maintaining K-RAS mediated transformation. Indeed, 
increased expression of NOX1 transcripts in colon 
cancer correlates with activating mutations in K-ras 
[50]. Moreover, Nox1 RNA interference reverts the 
K-RAS transformed phenotype, affecting anchorage-
independent growth, morphological changes and the 
production of tumors in athymic mice [53]. Therefore, 
mild mitochondrial mutants would be more tumorigenic 
due to the increased NOX1 levels that support the RAS 
mediated transformation. Confocal microscopy studies 
revealed that NOX1 localizes to the mitochondria and 
predominantly, to the perinuclear region [43] where it can 
induce mutations, genomic instability and changes in the 
methylation of nuclear DNA in a ROS-dependent manner, 
favoring neoplastic transformation [54]. In this respect, 
NOX1 may play a significant role in signal transduction 
and tumorigenesis enhancing redox signaling to the 
nucleus.
To evaluate the putative DNA damage induced in 
the different cell lines, we studied the phosphorylation 
of histone H2A.X in western blots (Figure 5E). 
Phosphorylation of the Ser-139 residue in the H2A.X 
histone variant is an early cellular response to the 
induction of DNA double-strand breaks (DSBs) and 
this may reflect cancer-associated genomic instability 
[55]. H2A.X phosphorylation was stronger in mild 
mitochondrial mutants (LHON cybrids and parental 143B 
cells) and it was lower in 143B ρ0 cells than in the controls. 
These results are well correlated with DNA damage and 
NOX1 expression, with the exception of the m.8363G>A 
cybrids in which H2A.X is more strongly phosphorylated 
relative to their low NOX1 expression. It is possible 
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Figure 6: Mild mtDNA mutations increase apoptosis resistance. (A) Growth curves in 4.5 g/L glucose showing no relevant 
differences among the cell lines (b) Proportion of apoptotic cells after 24 hours in the presence of staurosporine. Wild types clones for the 
V, H and Uk1 haplogroups were grouped. For mutants, the bars indicate the mean of two different clones. Duplicate measurements for each 
clone were obtained from three independent experiments and the error bars represent the standard deviations. The data was analyzed using 
one-way ANOVA and Tukey’s multiple comparison test, and a P-value <0.05 was considered significant: *=P ≤ 0.05, **=P ≤ 0.01, ***=P 
≤ 0.001. (c) Dot plots showing a representative assay for a wild type (high apoptosis) and for a mild mutant (low apoptosis).
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that the higher levels of mitochondrial superoxide in 
this cell line alone are sufficient to produce DSBs. 
Moreover, the greater genomic damage in mutants may 
even be enhanced by deficient repair as a consequence of 
inhibiting iron-sulphur cluster production [56]. Genomic 
instability is a driving force for tumorigenesis in which 
alterations to tumor cell genomes promote the acquisition 
of further DNA alterations, clonal evolution and finally, 
tumor heterogeneity, providing a selective advantage to 
overcome barriers [1]. Therefore, this increased genomic 
damage could contribute to the tumor phenotype in the 
mild mutants.
mtDNA-mediated tumorigenicity correlates with 
resistance to apoptosis
Since tumorigenicity reflects the balance between 
pro- and anti-oncogenic factors, producing a high 
proliferation and survival phenotype, we first elucidated 
whether the tumorigenic potential of the cybrids correlated 
with their proliferative capacity. The growth curves of the 
cybrids in high-glucose medium were similar (Figure 
6A), even though some lines had completely different 
tumorigenic properties (e.g., the parental 143B and WT(B) 
cells, Figure 2). Consequently, we hypothesized that the 
higher tumorigenicity of mild mutant cybrids may be 
derived, at least partially, from their enhanced survival. 
Thus, we studied the survival capacity of the cybrids after 
treatment with staurosporine, a well-known inducer of 
apoptosis in a wide range of cell lines [57]. Flow cytometry 
showed tumorigenic cells better resisted staurosporine-
induced apoptosis (e.g., m.14484T>C, m.3460G>A and 
m.11778G>A) than the non-tumorigenic WT (V, H, Uk1: 
Figure 6B), as did 143B cells with respect to the 143 ρ0, 
WT(B) and m.8363G>A, although in this latter case the 
differences were not statistically significant. This result at 
least in part explains the more tumorigenic properties of 
the mild mutants, indicating that they would be capable 
of generating more tumors since they are able to better 
resist the more astringent conditions in the organism. The 
effect of mtDNA variants on the apoptotic response of the 
cells has been evaluated in numerous studies with varying 
results, ranging from mtDNA mutations protecting cells 
Figure 7: summary. Mitochondrial DNA mild mutations induce tumor formation through complex retrograde signaling. (A) Schematic 
representation of the different pathways involved in the mitochondrial retrograde signal that may affect tumorigenic behavior described here 
or in the literature. We propose that small changes in OXPHOS function and ROS production trigger a complex mitochondrial retrograde 
response that ultimately enhances the tumorigenic phenotype: (↑) and (↓) indicate increase/activation or decrease/inhibition, respectively; 
(+) and (-) indicate increase/activation or decrease/inhibition mediated by ROS, respectively. (b) Relationship between mitochondrial 
function and tumorigenicity found in this study. (c) Table summarizing the different mitochondrial parameters measured (Data are the 
means and the units are shown in the results).
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from apoptosis [29, 46] to the contrary [58, 59], possibly 
due to the different approaches employed. 
One possible explanation for the enhanced 
resistance to apoptosis in mild mutants is related to the 
dependence of calcium homeostasis on MIMP (Figure 
1B, 3B). Mitochondrial calcium intake essentially occurs 
through the mitochondrial Ca2+ uniporter [60]. Since 
Ca2+ is essential for PTP opening, the reduced calcium 
concentration in the mitochondrial matrix due to the lower 
MIMP in mild mutant cybrids would impair the triggering 
of the apoptotic response. Furthermore, the differences in 
resistance to apoptosis can be explained by the multiple 
routes modified in response to a retrograde signal that 
triggers a complex nuclear response. It is likely that the 
mechanism that confers greater resistance to apoptosis in 
mild mutants is not activated in 143B ρ0 and m.8363G>A 
cell lines due to other pathways that exert a dominant 
effect over this process.
cONcLUsIONs 
In this study we present convincing evidence that 
genetic mtDNA variants modulate the tumorigenicity 
of the 143B osteosarcoma cell line, strongly suggesting 
that mtDNA rendering a functional or non-functional 
OXPHOS system does not support tumorigenicity, 
while mild mtDNA mutations are associated with 
tumorigenicity. We found two parameters directed related 
to the tumorigenic potential of the cell lines studied in our 
experimental model, resistance to apoptosis and increased 
NOX expression. In addition, the glycolytic rate, ROS 
levels and Hif1α stability also appear to be correlated 
with tumorigenicity, yet only within a given range 
(from unaffected to mildly-affected OXPHOS). Thus, 
tumorigenic potential probably arises as the result of a 
balance between several pro- and anti-tumorigenic factors 
that are modified as a consequence of mitochondrial 
dysfunction (Figure 7).
Our results suggest that the growth of tumor cells 
that carry mutated mtDNA that provokes only mild 
OXPHOS dysfunction will be favored with respect to 
those cells carrying either normal mtDNA or mutated 
mtDNA that markedly impairs OXPHOS, both of which 
act as tumor suppressors. This could explain the numerous 
and varied mtDNA mutations found in human tumors, 
most of which give rise to mild mitochondrial dysfunction, 
as well as the failure to associate a specific mtDNA 
mutation with a particular tumor type [12]. Any mtDNA 
mutation leading to mild OXPHOS dysfunction could be 
selected in tumors.
Our current understanding of how mitochondria 
influence cancer is still quite basic and much work is 
needed to better define this relationship. Thus, we must 
delve deeper into the biology of mitochondria in tumor 
cells and determine its relationship with the nuclear 
genome. To decipher the mechanisms involved in the 
retrograde signals that underlie this relationship will be 
essential to understand what role the mitochondria play 
in cancer, where mtDNA could become a diagnostic and 
prognosis indicator of clinical relevance.
MAtErIALs AND MEtHODs
transmitochondrial cybrid generation and 
culture conditions
To homogenize nuclear and environmental 
factors, transmitochondrial cybrids were generated on 
a osteosarcoma 143B ρ0 nuclear background by fusion 
with platelets, as described elsewhere [19, 20]. Written 
informed consent to use biological specimens for research 
purposes was obtained from all patients. The platelet 
mtDNA was first sequenced on an ABI 3710 sequencer 
(Applied Biosystems, Foster City, CA) and the variations 
in the mtDNA were analyzed using the Staden Package 
[61] to assign the samples to a mitochondrial haplogroup 
based on the mtDNA variations in the mitomap DB (http://
www.mitomap.org/MITOMAP). Individual clones were 
isolated by limiting dilution, and their mtDNA analyzed 
by RFLPs and sequencing. 
To minimize any potential influence of the nuclear 
background, all cybrids generated in this work come 
from a single 143B ρ0 clone, and they were isolated and 
analyzed biochemically, confirming the complete absence 
of mtDNA by quantitative PCR and in Southern blots 
(Cruz-Bermúdez et al., manuscript in preparation). In 
addition, to overcoming the potential variability in clones 
during cybridization [19, 62], we also analyzed at least two 
different clones for each cell line in all the experiments.
Cells were grown routinely at 37ºC in a humidified 
atmosphere containing 5% CO2, and in 4.5 g/L glucose 
DMEM supplemented with 10% fetal bovine serum, 50 
µg/mL uridine and antibiotics. The cells were maintained 
in medium containing 2 g/L Glucose and 2.5 g/L Galactose 
(Glu/Gal DMEM) for 24 hours prior to performing the 
experiments. Each cell line was checked for mycoplasma 
contamination during the experiments.
Measurement of oxygen consumption
The basal respiration of intact cells was measured at 
37ºC in Glu/Gal DMEM by high resolution respirometry 
using the Oroboros oxygragh-2k, as described previously 
[63]. The mean of at least three independent experiments 
is shown.
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MIMP and rOs measurements
Mitochondrial superoxide and cytoplasmic ROS 
were assessed using MitoSOXTM red (Invitrogen) and 
2’,7’-dichlorodihydrofluorescein diacetate (H2DCFDA, 
Invitrogen) respectively. The mitochondrial inner 
membrane potential (MIMP) was evaluated as the ratio 
of tetramethyl rhodamine ester (TMRE, Invitrogen) and 
MitoTracker Green (MTG, Invitrogen). For these assays, 
0.75x105 cells were grown in Glu/Gal DMEM. After 
addition of the fluorophores (5 µM MitoSOXTM, 30µM 
H2DCFDA or 100nM TMRE and 100nM MTG) and 
incubation at 37ºC for 30 min in the dark, the cells were 
collected in Glu/Gal DMEM and analyzed immediately 
with a Cytomic FC500 MPL flow cytometer (Beckman 
Coulter). Forward and side scatter were used to gate the 
viable population of cells, and the mean fluorescence 
intensity was determined with MXP software (Beckman 
Coulter). Experiments were performed in duplicate on at 
least three independent passages.
steady state AtP
Mitochondrial steady state ATP levels were 
measured in cells incubated previously with 1 mM 
pyruvate and 5mM 2-deoxy-D-glucose, an irreversible 
inhibitor of glucokinase, so that cells incubated with it and 
Pyruvate in the absence of a carbon source synthesizes 
ATP only in mitochondria. ATP was quantified using 
the luminometric luciferin-luciferase based method, as 
described elsewhere [64]. Experiments were performed in 
duplicate on at least three independent days.
Lactic acid measurement
Lactate was measured in the medium (Glu/
Gal DMEM) in which 105 cells had been plated and 
cultured for 48 h. Proteins were removed from 50 µL 
of the medium by adding 100 µl of 8% Percloric Acid 
and 40% EtOH at 4ºC, and centrifuging at 2x104 g for 
10 min at 4ºC. The supernatants were then frozen until 
the lactate in 15 µL of each sample, or lactate standard, 
was measured mixed with 150 µl of assay buffer (0.5M 
glycine [pH 9.5], 0.2M Hydrazine, 3.4mM EDTA), 100 
µl of H20, 5µL of 1100U/mL LDH (Roche) and 30µL 
of 15 mM NAD+. NADH production was evaluated by 
measuring absorbance at 340nm in a multiplate reader 
(Synergy HT, Biotek) and it was proportional to the lactic 
acid concentration in the sample after a 2 h incubation. 
The lactate concentration was normalized to the total 
amount of protein measured with the Micro BCA Protein 
Assay Kit (Thermo Scientific). Assays were performed in 
triplicate in three independent experiments.
cell growth assays
Cell growth was assayed after seeding in 6 well 
plates at a density of 25,000 cells/well and growing 
the cells for 4 days in DMEM containing either 4.5 g/L 
glucose or 0.9 g/L galactose as carbon source. The cells 
were harvested and counted every 24 hours. 
Measurement of apoptosis
Apoptosis was measured by staining cells 
simultaneously with Annexin V–FITC (green 
fluorescence) and the non-vital dye propidium iodide (PI; 
red fluorescence), discriminating intact (Annexin V-FITC 
negative, PI negative), early apoptotic (Annexin V-FITC 
positive, PI negative), late apoptotic (Annexin V-FITC 
positive, PI positive) and necrotic cells (Annexin V-FITC 
negative, PI positive). The proportion of necrotic cells was 
always below 1%.
Flow cytometry analysis was carried out using the 
MitoStep + FITC Apoptosis Detection Kit, according to 
the manufacturer´s instructions (Immunostep). Briefly, 
7.5x104 cells were seeded in Glu/Gal DMEM, apoptosis 
was induced by exposing them to 500nM Staurosporine 
for 24 hours and they were analyzed on a Cytomics 
FC500 MPL flow cytometer (Beckman Coulter). Assays 
were performed in duplicate in least three independent 
experiments.
Western blotting
HIF1, NOX1 and phopho-Histone H2A.X 
expression was analyzed in cells grown in hypoxic 
conditions (1% O2 for 24 h) using specific antibodies from 
BD Transduction Laboratories, Santa Cruz Biotechnology 
(sc-5281) and Cell Signaling (#9718), respectively. 
To analyze the phosphorylation levels of ERK1/2 and 
AKT, cells were deprived of serum for 12 h before lysis 
and the proteins were detected using specific antibodies 
(Cell Signaling). Tubulin immunodetection (sc-5286, 
Santa Cruz Biotechnology) was used as a control of 
protein loading. Appropriate horseradish peroxidase 
coupled secondary antibodies were used and peroxidase 
activity was assessed by enhanced chemoluminiscence 
(Amersham).
tumorigenicity assays
All animal experiments were approved by the 
Animal Care and Use Committees of the UAM and CSIC. 
Mice were house and handled following institutional 
guidelines for animal care and in accordance with the 
standards established in the “National Institutes of Health 
Guide for the Care and Use of Laboratory Animals”. 
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For tumorigenicity assays, 5x106 cells were injected 
intradermally/subcutaneously into the two flanks of 
8-week-old BALB/c female athymic nude mice (Harlan). 
The size of the tumors was calculated twice weekly over 
at least two months based on caliper measurements of two 
orthogonal diameters. The latency period was defined as 
the time needed for tumors to reach a size of 0.75 cm2.
statistics
The results are presented as the mean ± SD, and the 
statistical analysis was performed using one-way ANOVA 
and Tukey’s multiple comparison test. P-values ≤0.05 
were considered significant: *=P≤0.05, **=P≤0.01, ***=P 
≤0.001.
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